Valenti MT, Giannini S, Donatelli L, Realdi G, Lo Cascio V, Dalle Carbonare L
Zoledronic acid decreases mRNA STEAP expression in prostate cancer cells. [JOURNAL ARTICLE]
J Endocrinol Invest 2009 Nov 12.
Background. Zoledronic acid (Zol) is used successfully to inhibit bone resorption in tumour bone disease of various human cancer. Zol inhibits the mevalonate pathway and other potential targets include the inhibition of tyrosine phosphatase activity, disruption of metalloproteinase, secretion and down-regulation of the catalytic subunit of telomerase (hTERT). The six-transmembrane epithelial antigen of prostate protein (STEAP) is a new marker highly expressed at all phases of prostate cancer.
Aim. Here, we analyzed for the first time the effect of Zol on STEAP gene expression in prostate cancer cells. Material and Methods. We evaluated the effects of Zol in STEAP gene expression by RT Real Time PCR in androgen sensitive (LNCaP) and androgen non sensitive (PC3 and DU145). To confirm the pro-apoptotic effect of Zol, we also analyzed the caspase 3 gene expression, that resulted upregulated in cancer cell apoptosis.
Results. Zol strongly decreased cell viability and lowered STEAP gene expression in a dosedependent manner. In addition, this effect was accompanied by an increase of apoptotic index and an up-regulation of caspase-3 gene expression.
Conclusion. Zol may affect cancer cells also by targeting the gene expression of STEAP.
More from this journal |
